Enliven Therapeutics, Inc. Common Stock (ELVN) Financials
Key financial figures for Enliven Therapeutics, Inc. Common Stock (Q2 2026).
Enliven Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $32.5 million, or -$0.49 per share. Free cash flow for the period was -$18.6 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Enliven Therapeutics, Inc. are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$32M
- EPS
- $-0.49
- Total Assets
- $910M
- Operating Cash Flow
- -$19M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$32M | -$0.49 | -$19M | |
| Q1 FY2026 | $0 | -$24M | -$0.38 | -$19M | |
| Q4 FY2025 | $0 | -$30M | -$0.45 | -$16M | |
| Q3 FY2025 | $0 | -$20M | -$0.32 | ||
| Q2 FY2025 | $0 | -$25M | -$0.49 | -$17M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$104M | -$1.83 | -$70M | |
| FY2024 | $0 | -$89M | -$1.89 | -$73M | |
| FY2023 | $0 | -$72M | -$2.01 | -$61M |
Frequently asked questions
What was Enliven Therapeutics, Inc.'s revenue last quarter?
Enliven Therapeutics, Inc. reported revenue of $0.00 for Q2 FY2026.
Is Enliven Therapeutics, Inc. profitable?
Not in its most recent reported period. Enliven Therapeutics, Inc. reported a net loss of $32.5 million for Q2 FY2026.
How much free cash flow did Enliven Therapeutics, Inc. generate?
Enliven Therapeutics, Inc. generated free cash flow of -$18.6 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Enliven Therapeutics, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.